Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
Rozanolixizumab's EU approval for self-administration methods aims to improve patient autonomy and satisfaction by minimizing clinic visits. The phase 3 MG0020 study confirmed the safety and efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback